Enanta Pharmaceuticals | ENTA - Current Liabilities


Enanta Pharmaceuticals reported $44.73M in Current Liabilities for its fiscal quarter ending in December of 2025.





Current Liabilities Change Date
AbbVie USD 41.64B 458M Jun/2026
Amgen USD 25.5B 547M Jun/2026
Anika Therapeutics USD 22.15M 1.18M Jun/2026
Arrowhead Research USD 283.35M 11.87M Jun/2026
AstraZeneca USD 31.55B 1.02B Jun/2026
BioCryst Pharmaceuticals USD 208.85M 13.46M Jun/2026
Biogen USD 3.92B 918.2M Jun/2026
Bristol-Myers Squibb USD 18.66B 499M Jun/2026
Enanta Pharmaceuticals USD 44.73M 3.83M Dec/2025
Gilead Sciences USD 11.02B 1.54B Jun/2026
GlaxoSmithKline GBP 21.53B 895M Jun/2026
Halozyme Therapeutics USD 344.44M 18.77M Jun/2026
Heron Therapeutics USD 92.14M 1.63M Jun/2026
Immunic USD 38.36M 7.74M Mar/2026
Incyte USD 1.31B 177.55M Jun/2026
Insmed USD 438.74M 77.74M Jun/2026
Ionis Pharmaceuticals USD 315.64M 401.36M Jun/2026
J&J USD 54.9B 2.82B Jun/2026
Karyopharm Therapeutics USD 117.3M 25.24M Mar/2026
Ligand Pharmaceuticals USD 46.74M 6.07M Jun/2026
Merck USD 27.73B 786M Jun/2026
Neurocrine Biosciences USD 874.5M 42.8M Jun/2026
Novartis USD 31.75B 374M Jun/2026
Novavax USD 330.57M 11.89M Jun/2026
Pfizer USD 32.65B 1.7B Jun/2026
PTC Therapeutics USD 771.07M 152.54M Jun/2026
Roche Holding CHF 28.85B 846M Jun/2026
Sarepta Therapeutics USD 502.91M 3.74M Jun/2026
Vertex Pharmaceuticals USD 3.94B 57.3M Jun/2026